Lyme Disease Vaccine Shows Antibodies 6 Months after Completion
FDA Expands Ibrexafungerp Approval for Reduction of Recurrent Yeast Infection
FDA Approves First-Ever Fecal Microbiota, RBX2660, for C Difficile Recurrence
Type I Interferon Response Linked to Resistance to HCV Infection
